2025年将成为医美上游产品集中爆发的关键年份,这一趋势在近期密集的新品获批潮中已初现端倪。据不完全统计,仅过去一周就有七款创新产品通过国家药品监督管理局审批,覆盖注射填充、光电设备、减重药物等核心赛道。现将本轮获批产品矩阵梳理如下:01瑞士海雅美“提升针”在国内落地国际医美品牌瑞士海雅美宣布,其明星产品Hyamax海维纳斯·雅派正式获得NMPA三类医疗器械认证。该产品以32mg/mL高浓度透明质...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.